ERCP, a Recent Drug-Eluting Stent, and a Distal Biliary Stricture
58-year-old woman with painless jaundice, 6 kg weight loss, and a 12 mm common bile duct with a distal stricture on MRCP is referred for ERCP. She received a drug-eluting coronary stent 3 months ago and takes aspirin 81 mg plus clopidogrel. She has no fever or cholangitis. Total bilirubin is 9.2 mg/dL, alkaline phosphatase 480 U/L, and CA 19-9 is elevated. The cardiologist is unreachable until tomorrow. The endoscopy schedule is full, but the gastroenterology fellow offers to 'squeeze her in' today and perform a sphincterotomy if needed.
1. How do you decide whether to proceed with ERCP today, given the recent drug-eluting stent and dual antiplatelet therapy?
Read the worked answer
She has painless jaundice and a distal stricture but no fever or cholangitis, so ERCP is urgent rather than emergent. The recent drug-eluting stent (3 months) makes clopidogrel interruption a high thrombotic risk; do not stop dual antiplatelet therapy without cardiology input. Sphincterotomy while on clopidogrel increases bleeding risk.
Today: contact cardiology and document a plan. If drainage can wait 24-48 hours, defer until cardiology clears. If she develops cholangitis or progressive liver dysfunction, proceed with the lowest-risk drainage strategy, ideally avoiding sphincterotomy if a stent can be placed, and involve anesthesia. Do not let a full schedule pressure you into an unplanned sphincterotomy. Consent should specifically address stent thrombosis, bleeding, and the possibility of staged drainage.
2. What antibiotic and stent strategy do you use for a suspected distal malignant stricture?
Read the worked answer
Antibiotic prophylaxis is not routinely indicated for ERCP when complete biliary drainage is anticipated. Give prophylaxis if incomplete drainage is expected, if there is hilar stricture, or if cholangitis is present; in this patient, without cholangitis and with a distal stricture, decide based on the drainage plan.
For a presumed unresectable distal malignancy, a self-expandable metal stent provides longer patency. If she is potentially resectable or may receive neoadjuvant therapy, a plastic stent may be preferred to avoid interfering with surgery. Obtain tissue sampling first (brush cytology and/or forceps biopsy; cholangioscopy if needed) because a stent can make later sampling harder. Document the level of stricture and the drainage achieved.
3. What post-ERCP pancreatitis prevention and consent points apply?
Read the worked answer
She is at elevated risk for post-ERCP pancreatitis because of suspected malignant obstruction and any pancreatic duct instrumentation. If no contraindication, give rectal indomethacin 100 mg and aggressive lactated Ringer's hydration. Consider a prophylactic pancreatic stent if the pancreatic duct is inadvertently injected or high-risk maneuvers are performed.
Consent should include post-ERCP pancreatitis (commonly quoted around 5-10% in average risk, higher in high-risk cases), bleeding, perforation, infection/cholangitis, stent occlusion or migration, and the need for repeat procedures. Explain that the procedure is primarily for drainage and diagnosis, not cure, and that tissue sampling may be inconclusive. Document the cardiology discussion and the plan for antiplatelet therapy.